MARKET

MDWD

MDWD

Mediwound
NASDAQ
16.96
-0.65
-3.69%
Closed 16:00 05/23 EDT
OPEN
17.57
PREV CLOSE
17.61
HIGH
17.78
LOW
16.55
VOLUME
47.87K
TURNOVER
0
52 WEEK HIGH
19.86
52 WEEK LOW
7.10
MARKET CAP
160.98M
P/E (TTM)
-22.7620
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MDWD last week (0513-0517)?
Weekly Report · 3d ago
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/14 12:10
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/13 21:15
Weekly Report: what happened at MDWD last week (0506-0510)?
Weekly Report · 05/13 12:10
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/09 12:40
Weekly Report: what happened at MDWD last week (0429-0503)?
Weekly Report · 05/06 12:21
Weekly Report: what happened at MDWD last week (0422-0426)?
Weekly Report · 04/29 12:30
MediWound To Present New Data From EscharEx Phase II Studies At 3 Wound Care Conferences
Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and endpoints of the upcoming Phase III study. Clinical data will be presented throughout May 2024 at the largest annual meetings in the field of chronic wound care. Eschar ex is a bioactive, enzymatic debridement agent for the treatment of chronic wounds.
Benzinga · 04/25 12:32
More
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Webull offers Mediwound Ltd stock information, including NASDAQ: MDWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDWD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDWD stock methods without spending real money on the virtual paper trading platform.